Parameter
| Biomarker | EBV (Epstein-Barr virus) | Full name | Epstein-Barr virusMMMMMMMMM | Molecular Type | Viral nucleic acid (DNA/RNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, and prediction | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Tumor tissues (EBER in situ hybridization, NGS detection of EBV DNA), serum (EBV antibody detection) | ||
| Pathobiological Mechanisms | About 10% of gastric cancer is EBV-positive. After the viral genome is integrated into host cells, the NF-κB pathway is activated by the expression of EBER and LMP1 proteins, which promotes inflammatory response and immunosuppression (such as high expression of PD-L1) | ||||
| Clinical Availability Status | Clinically useful (subtype diagnosis/immunotherapy screening) : it is used for the diagnosis of EBV-associated gastric cancer and the prediction of immunotherapy efficacy | ||||
| Notes and Dynamics | As a specific diagnostic marker for EBV-associated gastric cancer, this subtype of patients has high PD-L1 expression rate, high tumor mutation burden (TMB), and significantly better response to ICIs treatment than other subtypes, which is a dominant population marker for immunotherapy | ||||